TLR4 and neoplasm: We demonstrate here in a bilateral model of A20 lymphoma that IT treatment of only one tumor with the synthetic TLR4 agonist GLA at the highest dose evaluated (50 μg) cured ~ 50% of mice, indicating the induction of a systemic immune response.